CPI-613 (devimistat) + Modified FOLFIRINOX
Borderline Resectable Pancreatic Adenocarcinoma
Key Facts
Indication
Borderline Resectable Pancreatic Adenocarcinoma
Phase
Phase 2
Status
Recruiting
Company
About Rafael Holdings
Rafael Holdings is a clinical-stage oncology company leveraging its expertise in cancer metabolism to develop innovative therapeutics. Its core asset, CPI-613, is a lipoate analog that disrupts key mitochondrial enzymes, inducing selective cancer cell death. The company is advancing CPI-613 through multiple clinical trials, primarily in combination regimens, and maintains a strategic focus on aggressive and rare cancers with high unmet need.
View full company profile